Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- BJU INTERNATIONAL110(11) · pp.1801 · 2012
- 피인용
- Web of Science 46
- JCR IF
- JCR 2011 2.844
- ISSN
- 1464-4096
저자
- Zhao, Chen제1저자Department of Urology, Chonbuk National University Medical School, Chonbuk National University Hospital, South Korea
- Kim, Sae WoongDepartment of Urology, College of Medicine, Catholic University, South Korea
- Yang, Dae YulDepartment of Urology, College of Medicine, Hallym University, South Korea
- Kim, Je JongDepartment of Urology, College of Medicine, Korea University, South Korea
- 박남철Department of Urology, College of Medicine, Pusan National University, South Korea
- Lee, Sung WonDepartment of Urology, College of Medicine, Sungkyunkwan University, South Korea
- Paick, Jae SeungDepartment of Urology, College of Medicine, Seoul National University, South Korea
- Ahn, Tai YoungDepartment of Urology, College of Medicine, Ulsan University, South Korea
- Moon, Ki HakDepartment of Urology, College of Medicine, Youngnam University, South Korea
- Chung, Woo SikDepartment of Urology, College of Medicine, Ihwa University, South Korea
- Min, Kweon SikDepartment of Urology, College of Medicine, Inje University, South Korea
- Suh, Jun-KyuDepartment of Urology, College of Medicine, Inha University, South Korea
- Hyun, Jae SeogDepartment of Urology, College of Medicine, Kyungsang National University, South Korea
- Park, KwangsungDepartment of Urology, College of Medicine, Chonnam National University, South Korea
- Park, Jong Kwan교신저자Department of Urology, Chonbuk National University Medical School, Chonbuk National University Hospital, South Korea
초록
OBJECTIVE To evaluate the efficacy and safety of avanafil, a new potent selective phosphodiesterase type 5 (PDE5) inhibitor, in patients with erectile dysfunction (ED). PATIENTS AND METHODS The present study was a multicentre, randomized, double-blind, placebo-controlled, fix-dosed phase three clinical trial involving 200 patients with ED. The subjects were treated with placebo or avanafil (100 or 200 mg) for 12 weeks and were asked to complete the International Index of Erectile Function (IIEF), the Sexual Encounter Profile (SEP) diary, and the Global Assessment Questionnaire (GAQ). The primary outcome variable was the change from baseline for IIEF erectile function domain (EFD) score. The secondary outcome variables were SEP Q2 and Q3, the shift to normal rate (EFD = 26), and response to the GAQ. RESULTS Compared with placebo, patients who took 100 or 200 mg of avanafil had significantly improved IIEF-EFD score. There were similar results when comparing Q2 and Q3 in the SEP diary and the GAQ. Flushing was the most common treatment-related adverse event. Most adverse events were transient and mild or moderate in severity. CONCLUSION Avanafil is an effective and well-tolerated therapy for ED of broad-spectrum aetiology and severity.
키워드
avanafilphosphodiesterase type 5 (PDE5) inhibitorerectile dysfunction (ED)clinical studyPHOSPHODIESTERASE-5 INHIBITORSUPDATESILDENAFIL
식별자
- WoS UID
- 000312245900047



로그인
연구물 목록으로